Mariane de Montalembert

List of Publications by Year
in descending order

134	5,592	147801	88630
papers	citations	31 h-index	70 g-index

137	137	137	5829
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Retinal atrophy and markers of systemic and cerebrovascular severity in homozygous sickle cell disease. European Journal of Ophthalmology, 2022, 32, 3258-3266.	1.3	2
2	Tocilizumab for severe acute chest syndrome in a child with sickle cell disease and dramatically high interleukinâ€6 values in endotracheal and pleural fluids. American Journal of Hematology, 2022, 97, .	4.1	3
3	Risk factors for severe <scp>COVID</scp>â€19 in hospitalized sickle cell disease patients: A study of 319 patients in France. American Journal of Hematology, 2022, 97, .	4.1	19
4	Young children formula consumption and iron deficiency at 24 months in the general population: A national-level study. Clinical Nutrition, 2021, 40, 166-173.	5.0	8
5	Effect of hydroxyurea exposure before puberty on sperm parameters in males with sickle cell disease. Blood, 2021, 137, 826-829.	1.4	30
6	Improved stenosis outcome in strokeâ€free sickle cell anemia children after transplantation compared to chronic transfusion. British Journal of Haematology, 2021, 193, 188-193.	2.5	9
7	Impact of sickle cell disease on patientsÊ¼ daily lives, symptoms reported, and disease management strategies: Results from the international <scp>Sickle Cell World Assessment Survey</scp> (<scp>SWAY</scp>). American Journal of Hematology, 2021, 96, 404-417.	4.1	66
8	CRISPR-Cas9 Gene Editing for Sickle Cell Disease and Î²-Thalassemia. New England Journal of Medicine, 2021, 384, 252-260.	27.0	939
9	Hydroxyurea does not affect the spermatogonial pool in prepubertal patients with sickle cell disease. Blood, 2021, 137, 856-859.	1.4	19
10	Chronic organ injuries in children with sickle cell disease. Haematologica, 2021, 106, 1535-1544.	3.5	8
11	<scp>Realâ€Life</scp> experience with hydroxyurea in patients with sickle cell disease: Results from the prospective <scp>ESCORTâ€HU</scp> cohort study. American Journal of Hematology, 2021, 96, 1223-1231.	4.1	29
12	Epidemiology and disease burden of sickle cell disease in France: A descriptive study based on a French nationwide claim database. PLoS ONE, 2021, 16, e0253986.	2.5	21
13	Biallelic mutations in the <i>SARS2</i> gene presenting as congenital sideroblastic anemia. Haematologica, 2021, 106, 3202-3205.	3.5	2
14	Clinical Prediction of Iron Deficiency at Age 2 Years: A National Cross-sectional Study in France. Journal of Pediatrics, 2021, 235, 212-219.	1.8	1
15	Recommendations for diagnosis and treatment of methemoglobinemia. American Journal of Hematology, 2021, 96, 1666-1678.	4.1	56
16	Appropriate thresholds for accurate screening for Î²-thalassemias in the newborn period: results from a French center for newborn screening. Clinical Chemistry and Laboratory Medicine, 2021, 59, 209-216.	2.3	1
17	The Liver in Sickle Cell Disease. Journal of Pediatric Gastroenterology and Nutrition, 2021, 72, 5-10.	1.8	5
18	Initial Safety and Efficacy Results from the Phase II, Multicenter, Open-Label Solace-Kids Trial of Crizanlizumab in Adolescents with Sickle Cell Disease (SCD). Blood, 2021, 138, 12-12.	1.4	5

#	Article	IF	Citations
19	Experiences of Sickle Cell Disease (SCD) Reported By Healthcare Professionals (HCPs) across Different Regions: International Sickle Cell World Assessment Survey (SWAY). Blood, 2021, 138, 3026-3026.	1.4	0
20	Implementation of Escort-HU Extension: European Sickle Cell Disease Cohort - Hydroxyurea - Extension Study : Interests and Methodology. Blood, 2021, 138, 3098-3098.	1.4	0
21	ERN-EuroBloodNet European Registry of Patients Affected by Red Blood Cell Disorders and COVID-19. Blood, 2021, 138, 4058-4058.	1.4	0
22	Limited Access to Transcranial Doppler Screening and Stroke Prevention for Children with Sickle Cell Disease in Europe: Results of a Multinational Eurobloodnet Survey. Blood, 2021, 138, 915-915.	1.4	4
23	Summary of Joint European Hematology Association (EHA) and EuroBloodNet Recommendations on Diagnosis and Treatment of Methemoglobinemia. HemaSphere, 2021, 5, e660.	2.7	1
24	One-Fifth of Children with Sickle Cell Anemia Show Exercise-Induced Hemoglobin Desaturation: Rate of Perceived Exertion and Role of Blood Rheology. Journal of Clinical Medicine, 2020, 9, 133.	2.4	6
25	Paediatric to adult transition care for patients with sickle cell disease: a global perspective. Lancet Haematology,the, 2020, 7, e329-e341.	4.6	22
26	IL-6 levels are dramatically high in the sputum from children with sickle cell disease during acute chest syndrome. Blood Advances, 2020, 4, 6130-6134.	5.2	6
27	Prognosis of patients with sickle cell disease and COVID-19: a French experience. Lancet Haematology,the, 2020, 7, e632-e634.	4.6	94
28	Mortality in children with sickle cell disease in mainland France from 2000 to 2015. Haematologica, 2020, 105, e440-443.	3.5	22
29	Anti-C5 antibody treatment for delayed hemolytic transfusion reactions in sickle cell disease. Haematologica, 2020, 105, 2694-2697.	3.5	23
30	Innate immune cells, major protagonists of sickle cell disease pathophysiology. Haematologica, 2020, 105, 273-283.	3.5	33
31	Sickle cell disease and malaria: decreased exposure and asplenia can modulate the risk from Plasmodium falciparum. Malaria Journal, 2020, 19, 165.	2.3	9
32	Paramacular temporal atrophy in sickle cell disease occurs early in childhood. British Journal of Ophthalmology, 2019, 103, 906-910.	3.9	12
33	Transfusing children with hemoglobinopathies. Transfusion Clinique Et Biologique, 2019, 26, 147-149.	0.4	1
34	Innate-like T cells in children with sickle cell disease. PLoS ONE, 2019, 14, e0219047.	2.5	4
35	Evaluation of Outcomes and Quality of Care in Children with Sickle Cell Disease Diagnosed by Newborn Screening: A Real-World Nation-Wide Study in France. Journal of Clinical Medicine, 2019, 8, 1594.	2.4	21
36	Hepatobiliary Complications in Children with Sickle Cell Disease: A Retrospective Review of Medical Records from 616 Patients. Journal of Clinical Medicine, 2019, 8, 1481.	2.4	35

#	Article	IF	Citations
37	Newborn Screening for Sickle Cell Disease in Europe. International Journal of Neonatal Screening, 2019, 5, 15.	3.2	17
38	Plasma histamine elevation in a large cohort of sickle cell disease patients. British Journal of Haematology, 2019, 186, 125-129.	2.5	7
39	AB1071â€…AUTO-IMMUNE AND INFLAMMATORY DISEASES IN CHILDREN WITH SICKLE CELL DISEASE: DIAGNOSTIC AND THERAPEUTIC ISSUES. , 2019, , .		0
40	Insights into determinants of spleen injury in sickle cell anemia. Blood Advances, 2019, 3, 2328-2336.	5.2	26
41	EHA Research Roadmap on Hemoglobinopathies and Thalassemia: An Update. HemaSphere, 2019, 3, e208.	2.7	13
42	Management Strategies and Satisfaction Levels in Patients with Sickle Cell Disease: Interim Results from the International Sickle Cell World Assessment Survey (SWAY). Blood, 2019, 134, 1017-1017.	1.4	2
43	Impact of Sickle Cell Disease Symptoms on Patients' Daily Lives: Interim Results from the International Sickle Cell World Assessment Survey (SWAY). Blood, 2019, 134, 2297-2297.	1.4	1
44	Effect of Hydroxyurea Exposure before Puberty on Sperm Parameters in Males with Sickle Cell Disease. Blood, 2019, 134, 889-889.	1.4	1
45	Results from the Completed Hgb-205 Trial of Lentiglobin for Î²-Thalassemia and Lentiglobin for Sickle Cell Disease Gene Therapy. Blood, 2019, 134, 3358-3358.	1.4	11
46	Concomitant Hydroxyurea and Voxelotor: Results from the HOPE Study. Blood, 2019, 134, 1003-1003.	1.4	6
47	Sickle cell disease: a comprehensive program of care from birth. Hematology American Society of Hematology Education Program, 2019, 2019, 490-495.	2.5	15
48	Crizanlizumab Versus Placebo, with or without Hydroxyurea/Hydroxycarbamide, in Adolescent and Adult Patients with Sickle Cell Disease and Vaso-Occlusive Crises: A Randomized, Double-Blind, Phase III Study (STAND). Blood, 2019, 134, 998-998.	1.4	5
49	Evaluation of Outcomes and Quality of Care in Children with Sickle Cell Disease Diagnosed By Newborn Screening: A Real-World Nation-Wide Study in France. Blood, 2019, 134, 1001-1001.	1.4	0
50	Hepcidin, Soluble Transferrin Receptor, and Other Biomarkers of Iron Status Distributions in Healthy 2 Years Old Infants from a National Ambulatory Study in France. Blood, 2019, 134, 4809-4809.	1.4	0
51	Stenosis Outcome at 1 and 3 Years after Transplantation Vs Standard-Care in Children with Sickle-Cell Anemia and Abnormal Transcranial Doppler with Stroke or No-Stroke History. Blood, 2019, 134, 2271-2271.	1.4	6
52	Gene Therapy in Patients with Transfusion-Dependent Î²-Thalassemia. New England Journal of Medicine, 2018, 378, 1479-1493.	27.0	525
53	Transfusionâ€related adverse events are decreased in pregnant women with sickle cell disease by a change in policy from systematic transfusion to prophylactic oxygen therapy at home: A retrospective survey by the international sickle cell disease observatory. American Journal of Hematology, 2018, 93, 794-802.	4.1	12
54	Early Noninvasive Ventilation and Nonroutine Transfusion for Acute Chest Syndrome in Sickle Cell Disease in Children: A Descriptive Study. Pediatric Critical Care Medicine, 2018, 19, e235-e241.	0.5	17

#	Article	IF	Citations
55	Very low prevalence of iron deficiency among young French children: A national crossâ€sectional hospitalâ€based survey. Maternal and Child Nutrition, 2018, 14, .	3.0	10
56	Clinical Outcomes Associated With Sickle Cell Trait. Annals of Internal Medicine, 2018, 169, 619.	3.9	78
57	Prognostic factors of disease severity in infants with sickle cell anemia: A comprehensive longitudinal cohort study. American Journal of Hematology, 2018, 93, 1411-1419.	4.1	17
58	Overview of Growth Development in Pediatric Patients Treated with Hydroxyurea (HU) in the Escort-HU Study. Blood, 2018, 132, 1079-1079.	1.4	0
59	Sickle cell disease. Lancet, The, 2017, 390, 311-323.	13.7	639
60	Gene Therapy in a Patient with Sickle Cell Disease. New England Journal of Medicine, 2017, 376, 848-855.	27.0	567
61	Prevalence and risk factors for red blood cell alloimmunization in 175 children with sickle cell disease in a French university hospital reference centre. British Journal of Haematology, 2017, 177, 641-647.	2.5	35
62	Recommendations regarding splenectomy in hereditary hemolytic anemias. Haematologica, 2017, 102, 1304-1313.	3.5	138
63	Family cord blood banking for sickle cell disease: a twenty-year experience in two dedicated public cord blood banks. Haematologica, 2017, 102, 976-983.	3.5	8
64	Associations between environmental factors and hospital admissions for sickle cell disease. Haematologica, 2017, 102, 666-675.	3.5	29
65	Anemia in children: prevalence, causes, diagnostic work-up, and long-term consequences. Expert Review of Hematology, 2017, 10, 1023-1028.	2.2	87
66	Visual Function in Asymptomatic Patients With Homozygous Sickle Cell Disease and Temporal Macular Atrophy. JAMA Ophthalmology, 2017, 135, 1100.	2.5	19
67	Design of the DREPAGREFFE trial: A prospective controlled multicenter study evaluating the benefit of genoidentical hematopoietic stem cell transplantation over chronic transfusion in sickle cell anemia children detected to be at risk of stroke by transcranial Doppler (NCT 01340404). Contemporary Clinical Trials, 2017, 62, 91-104.	1.8	11
68	Are the risks of treatment to cure a child with severe sickle cell disease too high?. BMJ: British Medical Journal, 2017, 359, j5250.	2.3	7
69	Management of iron overload in hemoglobinopathies. Transfusion Clinique Et Biologique, 2017, 24, 223-226.	0.4	20
70	Cardiac iron overload in chronically transfused patients with thalassemia, sickle cell anemia, or myelodysplastic syndrome. PLoS ONE, 2017, 12, e0172147.	2.5	44
71	Off-Label Prescription of Hydroxycarbamide (Hydroxyurea, HU) for Severe Anemia: Preliminary Results from European Non-Interventional, Multicentric, Prospective Escort-HU Study. Blood, 2017, 130, 758-758.	1.4	1
72	The First Two Years of Life in Sickle Cell Anemia Infants: Results of a Comprehensive Longitudinal Study. Blood, 2017, 130, 688-688.	1.4	0

#	Article	IF	Citations
73	279. Clinical Outcomes of Gene Therapy with BB305 Lentiviral Vector for Sickle Cell Disease and Î²-Thalassemia. Molecular Therapy, 2016, 24, S111-S112.	8.2	5
74	Longitudinal MRI and Ferritin Monitoring of Iron Overload in Chronically Transfused and Chelated Children With Sickle Cell Anemia and Thalassemia Major. Journal of Pediatric Hematology/Oncology, 2016, 38, 497-502.	0.6	8
75	Update from the Hgb-205 Phase 1/2 Clinical Study of Lentiglobin Gene Therapy: Sustained Clinical Benefit in Severe Hemoglobinopathies. Blood, 2016, 128, 2311-2311.	1.4	4
76	Assessment of Hematological Data in a Cohort of European Children with Sickle Cell Anemia Treated with Hydroxyurea: Can European Centers Apply Today the Lessons from the Twitch Study?. Blood, 2016, 128, 2494-2494.	1.4	2
77	Comparison of the Safety Profile of Sickle Cell Disease Patients Treated with Hydroxycarbamide in Off-Label Versus in-Label Prescriptions in the Escort-HU Non Interventional, Prospective, Observational Open-Label Cohort Study. Blood, 2016, 128, 2497-2497.	1.4	0
78	Pregnancy in sickle cell disease is at very high risk. Blood, 2015, 125, 3216-3217.	1.4	9
79	How I manage cerebral vasculopathy in children with sickle cell disease. British Journal of Haematology, 2015, 170, 615-625.	2.5	32
80	A biomimetic microfluidic chip to study the circulation and mechanical retention of red blood cells in the spleen. American Journal of Hematology, 2015, 90, 339-345.	4.1	65
81	Erythroid Adhesion Molecules in Sickle Cell Anaemia Infants: Insights Into Early Pathophysiology. EBioMedicine, 2015, 2, 154-157.	6.1	11
82	13â€valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6â€17 years of age with sickle cell disease previously vaccinated with 23â€valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study. Pediatric Blood and Cancer, 2015, 62, 1427-1436.	1.5	31
83	Cerebral haemorrhagic risk in children with sickleâ€cell disease. Developmental Medicine and Child Neurology, 2015, 57, 187-193.	2.1	32
84	Outcomes of Gene Therapy for Severe Sickle Disease and Beta-Thalassemia Major Via Transplantation of Autologous Hematopoietic Stem Cells Transduced Ex Vivo with a Lentiviral Beta AT87Q-Globin Vector. Blood, 2015, 126, 202-202.	1.4	28
85	Assessment of Cardiac Iron Overload in Chonically Transfused Patients with Thalassemia, Sickle Cell Anemia, and Myelodysplastic Syndromes. Blood, 2015, 126, 2151-2151.	1.4	0
86	Severe Nocturnal and Postexercise Hypoxia in Children and Adolescents with Sickle Cell Disease. PLoS ONE, 2014, 9, e97462.	2.5	44
87	Transition from paediatric to adult care for patients with sickle cell disease. British Journal of Haematology, 2014, 164, 630-635.	2.5	49
88	Imbalanced coagulation profile as a biomarker of migraine in children with sickle cell: Is this a link with cerebral ischemia?. Journal of Pediatrics, 2014, 165, 645-646.	1.8	2
89	Study Hgb-205: Outcomes of Gene Therapy for Hemoglobinopathies Via Transplantation of Autologous Hematopoietic Stem Cells Transduced Ex Vivo with a Lentiviral Î²Î'-T87Q-Globin Vector (LentiGlobinÂ®) Tj ETQq1 1 0.784314 rgBT /Ov	1.4	
90	A Multicentre Study of Environmental Factors on the Severity of Sickle Cell Disease. Blood, 2014, 124, 4841-4841.	1.4	0

#	Article	IF	Citations
91	Erythroid Adhesion Molecule Expression Profile in Sickle Cell Anemia Infants. Blood, 2014, 124, 1368-1368.	1.4	0
92	Implementation of a European Cohort to Follow Sickle Cell Children and Adults Treated with Hydroxycarbamide. Blood, 2014, 124, 564-564.	1.4	1
93	GATA 1: pArg202Thr, a New GATA 1 Mutation Involved in a Severe Dyserythropoietic Phenotype. Blood, 2014, 124, 1343-1343.	1.4	0
94	Combined blood transfusion and hydroxycarbamide in children with sickle cell anaemia. British Journal of Haematology, 2013, 160, 259-261.	2.5	19
95	Relationship between vitamin D deficiency and bone fragility in sickle cell disease: A cohort study of 56 adults. Bone, 2013, 52, 206-211.	2.9	52
96	To SWiTCH or not to SWiTCH?. Blood, 2012, 119, 3870-3871.	1.4	4
97	Right Ventricular Systolic Strain Is Altered in Children with Sickle Cell Disease. Journal of the American Society of Echocardiography, 2012, 25, 511-517.	2.8	38
98	Acute splenic sequestration crisis in sickle cell disease: cohort study of 190 paediatric patients. British Journal of Haematology, 2012, 156, 643-648.	2.5	89
99	Relationship Between vitamin D Deficiency and Bone Fragility in Sickle Cell Disease: A Cohort Study of 56 adults.. Blood, 2012, 120, 2103-2103.	1.4	1
100	Children with Sickle Cell Anemia Experience Severe Oxygen Desaturation During Night and After Six-Minute Walk Distance Test. Blood, 2012, 120, 4766-4766.	1.4	1
101	Intracranial Aneurysms in Children with Sickle-Cell Anemia. Blood, 2012, 120, 4756-4756.	1.4	0
102	A 2-Dose Schedule of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Given to Children with Sickle Cell Disease Previously Immunized with 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23): Results of a Phase 3 Study. Blood, 2012, 120, 3212-3212.	1.4	2
103	Delayed hemolytic transfusion reaction in children with sickle cell disease. Haematologica, 2011, 96, 801-807.	3.5	86
104	ENERCA clinical recommendations for disease management and prevention of complications of sickle cell disease in children. American Journal of Hematology, 2011, 86, 72-75.	4.1	33
105	Sickle cell disease: primum non nocere (first do no harm). Haematologica, 2010, 95, 4-5.	3.5	6
106	Feasibility and efficacy of chronic transfusion for stroke prevention in children with sickle cell disease. European Journal of Haematology, 2010, 84, 259-265.	2.2	46
107	Complications and treatment of patients with Â-thalassemia in France: results of the National Registry. Haematologica, 2010, 95, 724-729.	3.5	93
108	Chronic Ironâ€deficiency Anemia Caused by a Jejunojejunal Intussusception on a Solitary Hamartomatous Polyp. Journal of Pediatric Gastroenterology and Nutrition, 2010, 50, 450-452.	1.8	1

#	Article	IF	Citations
109	Does regular blood transfusion prevent progression of cerebrovascular lesions in children with sickle cell disease?. Annals of Hematology, 2009, 88, 785-788.	1.8	65
110	Current strategies for the management of children with sickle cell disease. Expert Review of Hematology, 2009, 2, 455-463.	2.2	7
111	Acute Splenic Sequestration in Sickle Cell Disease (SCD): Still a Life Threatening Complication. Blood, 2008, 112, 4811-4811.	1.4	0
112	Bone Mineral Density in Children with Sickle Cell Disease (SCD) Is Low and Not Related to Disease Severity, Vitamin D Status, or Bone Hyperresorption. Blood, 2008, 112, 4793-4793.	1.4	68
113	Sickle cell disease as a paradigm of immigration hematology: new challenges for hematologists in Europe. Haematologica, 2007, 92, 865-871.	3.5	86
114	Endothelial-dependent vasodilation is impaired in children with sickle cell disease. Haematologica, 2007, 92, 1709-1710.	3.5	41
115	Immunogenicity and Safety of a Pneumococcal Conjugate 7-Valent Vaccine in Infants With Sickle Cell Disease. Pediatric Infectious Disease Journal, 2007, 26, 1105-1109.	2.0	28
116	Posttraumatic stress disorder in children affected by sickle-cell disease and their parents. American Journal of Hematology, 2007, 82, 171-172.	4.1	36
117	Pyruvate Kinase (PK) Deficiency in Newborns: The Pitfalls of Diagnosis. Journal of Pediatrics, 2007, 150, 443-445.	1.8	10
118	Phlebotomy and Bolus Subcutaneous Deferoxamine in Algerian Patients with Thalassemia Major or Intermedia or Sickle Cell Disease Treated with Hydroxyurea.. Blood, 2007, 110, 3812-3812.	1.4	0
119	Two new human DMT1 gene mutations in a patient with microcytic anemia, low ferritinemia, and liver iron overload. Blood, 2006, 107, 4168-4170.	1.4	109
120	Socio-Economic Impact of Infused Iron Chelation Therapy in France: ISOSFER Study Results.. Blood, 2006, 108, 3354-3354.	1.4	3
121	Endothelial-Dependent Vasodilation Is Impaired in Children with Sickle Cell Disease (SCD).. Blood, 2006, 108, 3778-3778.	1.4	0
122	Regular Blood Transfusion Does Not Prevent Progression of Cerebral Lesions Evidenced by Magnetic Resonance Imaging in Children with Sickle Cell Disease (SCD).. Blood, 2006, 108, 792-792.	1.4	0
123	Evolution of Transfusion Requirement in Algerian Thalassemic Major (TM) and Intermediate (TI) Patients Treated with Hydroxyurea (HU).. Blood, 2006, 108, 1588-1588.	1.4	9
124	Long-term hydroxyurea treatment in children with sickle cell disease: tolerance and clinical outcomes. Haematologica, 2006, 91, 125-8.	3.5	70
125	Pharmacokinetics of hydroxyurea 1,000 mg coated breakable tablets and 500 mg capsules in pediatric and adult patients with sickle cell disease. Haematologica, 2006, 91, 1685-8.	3.5	30
126	Psychological Outcome after Hematopoietic Cell Transplantation for Sickle Cell Disease.. Blood, 2005, 106, 2021-2021.	1.4	3

#	Article	IF	Citations
127	Two New Human DMT1 Mutations in a Compound Heterozygous Patient with Microcytic Anemia and Low Iron Stores.. Blood, 2005, 106, 3540-3540.	1.4	1
128	Acute Hepatic Crisis in Children With Sickle Cell Disease. Journal of Pediatric Gastroenterology and Nutrition, 2004, 39, 200-202.	1.8	11
129	Myocardial perfusion in children with sickle cell disease. American Journal of Cardiology, 2003, 91, 374-376.	1.6	11
130	Hydroxyurea can eliminate transfusion requirements in children with severe Î²-thalassemia. Blood, 2003, 102, 1529-1530.	1.4	111
131	Acute clinical events in 299 homozygous sickle cell patients living in France. European Journal of Haematology, 2000, 65, 155-164.	2.2	108
132	The relative importance of the Xâ€linked FCP locus and Î²â€globin haplotypes in determining haemoglobin F levels: a study of SS patients homozygous for Î² S haplotypes. British Journal of Haematology, 1997, 96, 806-814.	2.5	57
133	Epidemiological and clinical study of sickle cell disease in France, French Guiana and Algeria. European Journal of Haematology, 1993, 51, 136-140.	2.2	31
134	Absence of HIV DNA Sequences in Seronegative Polytransfused Thalassemic Patients. Vox Sanguinis, 1990, 59, 218-221.	1.5	1